Press Releases

NeoTX Announces Poster Presentation at ASCO 2024 Annual Meeting

May 28, 2024
REHOVOT, Israel
REHOVOT, ISRAEL – May 28, 2024 NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, announced abstract acceptance at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting being held May 31- June 4, 2024, at the McCormick Place, Chicago, IL. The poster will present preliminary results of clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in a phase 2 trial in patients with advanced/ metastatic non-small cell lung cancer (NSCLC) which have been pretreated with standard chemotherapy and a checkpoint inhibitor (CPI). Details on the presentation are as follows:
  • Abstract Title:
    Clinical Activity and Safety of Naptumomab Estafenatox (NAP) and Docetaxel in Patients (pts) with Checkpoint Inhibitor (CPI) Pre-treated Advanced/ Metastatic Non-Small Cell Lung Cancer (NSCLC) – Preliminary Results, P2 Trial
  • Abstract Number:
    8615
  • Session Type and Title:
    Poster Session – Lung Cancer—Non-Small Cell Metastatic
  • Session Date & Time:
    Monday June 3, 2024, 1:30 PM – 4:30 PM CDT
  About NeoTX NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com Investor and Media Contact: Robert Harow, CFOO NeoTX Therapeutics Ltd robert@neotx.com +1 609-718-2305 x204 +972 3 912 5853 x204

NeoTX Announces Clinical Trial Poster Presentation at AACR 2023 Annual Meeting

April 16, 2023
REHOVOT, Israel

REHOVOT, ISRAEL – April 11, 2023

NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, announced abstract acceptance at the American Association for Cancer Research (AACR) 2023 Annual Meeting being held April 14-19, 2023, at the Orange County Convention Center, Orlando, Florida. The poster will present the results of safety and preliminary activity in a phase 1b dose escalation trial of naptumomab estafenatox (NAP) combined with durvalumab in patients with advanced or metastatic solid tumors.

Details on the presentation are as follows:

  • Abstract Title: Safety and Preliminary Activity of Naptumomab Estafenatox (NAP) and Durvalumab in Patients with Advanced or Metastatic Solid Tumors: Interim results from a Phase 1b Trial
  • Abstract Number: CT205
  • Location:Poster Section 46
  • Poster Board Number:18
  • Session Title: Phase I Clinical Trials
  • Session Date & Time: Tuesday Apr 18, 2023, 9:00 AM – 12:30 PM

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com

Investor and Media Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com
+1 609-718-2305 x204
+972 3 912 5853 x204

NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)

June 1, 2022
REHOVOT, Israel

REHOVOT, ISRAEL- June 1, 2022  

NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, announced today the successful completion of the first stage of a Simon 2 stage Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). The patients were treated with NAP (10 μg/kg/day x 4, days 1-4) and with docetaxel 75mg/m2, on day 5. The first stage of this trial required a minimum of two responses out of ten patients and the second stage is now enrolling.

 “These early observations are encouraging as patients with advanced disease previously treated with chemotherapy and checkpoint inhibitors have limited treatment options and new alternatives are needed. In addition, this clinical milestone occurs just as the acquisition of InterX has been recently completed, adding a computer-aided drug discovery arm (CADD) to the pre-clinical and clinical capabilities of NeoTX. So, this has been a crucial time for us” said Asher Nathan, CEO of NeoTX. “NeoTX’s drug discovery capabilities are strengthened by a world-class team that includes three Nobel Laureates. InterX technologies have the potential to significantly increase the speed of drug discovery. InterX also provided a pipeline that includes an oral PD-L1 inhibitor, which aligns with our current development plan of investigating NAP in combination with CPIs in various indications.”

 

About NeoTX

NeoTX is a clinical-stage company developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors: NCT03983954, and NCT04880863. NeoTX’s computer aided drug discovery (CADD) subsidiary utilizes groundbreaking technology to dramatically decrease drug discovery times. . For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com
+1 609-718-2305 x204
+972 3 912 5853 x204

NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM

May 12, 2022
REHOVOT, Israel
REHOVOT and TEL AVIV, ISRAEL; MENLO PARK and BERKELEY, CALIFORNIA.  — May 12, 2022 – NeoTX announced today the acquisition of InterX. InterX, is a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel Prize Laureate Prof Michael Levitt’s discoveries. These tools allow a detailed quantum mechanical process assessment of biochemical interactions resulting in faster, more accurate and efficient drug discovery. In addition to the discovery engine, this acquisition also comes with a pipeline of early drugs. “We are excited to be expanding NeoTX capabilities to include a suite of proprietary drug discovery technologies. InterX is a world class team that includes three Nobel Laureates who have developed technologies that have the potential to increase the speed of drug discovery. These technologies augment traditional Computer Assisted Drug Discovery (CADD) and are designed to replace much of the typical synthesis and testing cycles that are needed after obtaining results from the traditional CADD process, while potentially saving three-plus years of the typical drug discovery timeline” said CEO, Asher Nathan. “InterX’s technology is the most advanced in the industry, and when combined with the development expertise of NeoTX, we will be able to advance best-in-class drug candidates, increase the value of our pipeline, and strive to contribute to improvement of quality of life within society,” said Nobel Prize Laureate Prof. Roger Kornberg, Chief Scientist of NeoTX and cofounder of InterX. InterX will benefit from the experience and infrastructure of NeoTX while maintaining a culture of innovation and creativity. Post-merger, Prof. Kornberg has also assumed the role of Chairman of the Board of NeoTX. About NeoTX NeoTX is a clinical-stage company developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com About InterX InterX is a drug development company, based in the United States and Israel, which is revolutionizing biomolecular computation of chemical and biological systems. The company aims to achieve robust and accurate prediction of molecular and ensemble properties of biological systems using computational methods. InterX is led by Nobel Prize-winning scientist Roger Kornberg. For more information, please visit www.interx.dev   Media Contact: Aviram Uzi Head of PR and Communications Gelbart-Kahana Investor Relations aviram@gk-biz.com +972-525329103   Investor Contact: Robert Harow, CFOO NeoTX Therapeutics Ltd robert@neotx.com 609-718-2305 x204  

NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer

January 31, 2022
REHOVOT, Israel

Rehovot, Israel — Jan 31, 2022 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced the promotion of current CMO, Marcel Rozencweig, M.D., to President and the appointment of Scott Z. Fields, M.D., as the new chief medical officer, effective tomorrow, Feb 01, 2022.   Dr. Fields brings more than 30 years of experience in clinical drug development and has been previously the Senior Vice President and Pharmaceutical Development Head, Oncology at Bayer Pharmaceuticals (OTC: BAYRY). 645382

“We are thrilled that Marcel will be the President to lead NeoTX in its next chapter of growth and success.  He has been a key part of NeoTX growth since its inception and, in his new role as President, will help to accelerate growth and expand strategic industry partnerships” said Asher Nathan, Ph.D., chief executive officer of NeoTX.

“I am very pleased and looking forward to leading, as President, in NeoTX’s advancement” said Dr. Rozencweig.  “Additionally, as a founding member of NeoTX, it gives me great pleasure to welcome Dr. Fields to our leadership team.”

“We, at NeoTX, are delighted that Scott is bringing his strong industry and operational leadership, which will prove valuable for our clinical development and registration strategies.  His broad experience in oncology drug development, with over a dozen drug approvals, is an excellent fit with our vision.” said Asher Nathan, Ph.D., chief executive officer of NeoTX.

“I’m thrilled to join NeoTX at this time of important growth and evolution of the company,” said Dr. Fields. “Together with our experienced leadership team, I look forward to helping the company accelerate the development of our pipeline and bring innovative new medicines to patients.”

As Global Head of Development for Oncology at Bayer Pharmaceuticals, Dr. Fields was responsible for early and late-stage development including several novel oncology medicines across the platforms for targeted therapies/precision medicine, antibody drug/alpha radiation conjugates and novel Immuno-Oncology agents. His group was responsible for the development and global registration of Darolutamide – a next generation androgen receptor inhibitor for prostate cancer and with partner Loxo, for Larotrectinb – a tissue agnostic NTRK inhibitor.  He was also responsible for the Oncology Operations, Project Management, Regulatory, Biomarkers, Biostatistics and Medical Writing groups. Prior to his position at Bayer, Dr. Fields held senior positions at Vertex Pharmaceuticals (NASDAQ: VRTX), SmithKline Beecham (NYSE: GSK), Amgen (NASDAQ: AMGN), Eisai (OTC: ESALY), and Arno Therapeutics (OTC: ARNI) and helped bring over a dozen drugs to market. He also practiced oncology/hematology and transplant medicine in academic settings.  Dr. Fields received his medical degree from SUNY Downstate Medical Center in New York, followed by training in internal medicine, hematology and oncology at Columbia University Medical Center.

 

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for non-small cell lung cancer and other solid tumors. For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi

Head of PR and Communications

Gelbart-Kahana Investor Relations

aviram@gk-biz.com

+972-525329103

 

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com 
609-718-2305 x204

 

Data on Naptumomab Estafenatox (NAP) Enhancing CAR-T cells Potency Presented by NeoTX at SITC 2021 Annual Meeting.

November 30, 2021
REHOVOT, Israel

Rehovot, Israel — November 30, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced that the preclinical data on naptumomab estafenatox (NAP) enhancing the potency of CAR-T cells was presented on Nov 12th at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting at the Walter E. Washington Convention Center, Washington D.C.

Clinical CAR-T therapy currently has limited efficacy against solid tumors due to low trafficking to the tumor, limited cell expansion in patients, tumor antigen heterogeneity, and an immunosuppressive microenvironment. NeoTX presented data that shows that NAP generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro. NAP is a fusion protein that consists of genetically engineered Superantigens (Sag) linked to Fragment antigen-binding (Fab) moieties directed to tumor-associated antigens, turns “cold tumors hot” and, in preclinical models, can lead to long-term memory responses.

The ability of NAP administration to activate T cells outside of the immunosuppressive microenvironment, promote T cell infiltration into the tumor and induce long-term memory responses strongly suggests that the combination of CAR-T cells with NAP may overcome the limited effect of CAR-T therapy against solid tumors. To access the presented poster, please click here.

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for non-small cell lung cancer and other solid tumors. For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com 
609-718-2305 x204

NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

November 9, 2021
REHOVOT, Israel

REHOVOT, Israel – November 9, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, today announced a presentation on the company’s lead program, naptumomab estafenatox (NAP), at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021 at the Walter E. Washington convention Center, Washington D.C.  The poster presentation will highlight preclinical data demonstrating that NAP enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors.

Details on the poster presentation are as follows:

  • Title: Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors
  • Abstract Number: 576 (ePoster)
  • Lead Author: Yael Sagi, Ph.D.
  • Category: Combination Immunotherapies
  • Date & Time: The ePoster will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com 
609-718-2305 x204

NeoTX Announces First Patient Enrolled In Phase 2a Clinical Trial Of Naptumomab Estafenatox (NAP), Its Lead Tumor Targeted Superantigen (TTS) Candidate, In Combination With Docetaxel In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

October 20, 2021
REHOVOT, Israel

REHOVOT, Israel – October 20, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that the first patient has been enrolled in the company’s phase 2a clinical trial of naptumomab estafenatox (NAP), its lead Tumor Targeted Superantigen (TTS) candidate, in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).

 “Dosing of the first patient in this phase 2 trial represents a crucial step forward for the clinical advancement of NAP” said Asher Nathan, Ph.D., chief executive officer of Neo TX. “This trial is based on promising phase 1 data. NSCLC is one of the deadliest cancers, and we are looking forward to evaluating NAP in this setting”.

 The phase 2a, open label trial in the US, will assess NAP in combination with docetaxel in patients who had been previously treated with checkpoint inhibitors and have advanced or metastatic NSCLC.  The primary endpoint is objective response rate as measured by RECIST 1.1 criteria.  The trial will also evaluate safety, duration of response, progression free survival, overall survival, pharmacokinetics, and pharmacodynamics. For more information about the trial, visit https://clinicaltrials.gov/ct2/show/NCT04880863

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com
609- 718-2305

Key Opinion Leader Webinar on Overcoming Check Point Inhibitor Resistance and Update on NeoTX TTS Platform

July 14, 2021
REHOVOT, Israel

REHOVOT, Israel —July 14, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, hosted a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14, 2021.

The webinar featured a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who discussed New Frontiers for Checkpoint Inhibitors in Immuno-Oncology. NeoTX’s management gave an update on their Tumor Targeted Superantigen (TTS) platform’s lead candidate, naptumomab estafenatox (NAP) in overcoming resistance. NAP is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management answered questions following the formal presentations.

To watch the webinar recording, please click here.

 About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information,

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751-4366
cait@lifescicomms.com

NeoTX Hosting Key Opinion Leader Webinar on Overcoming Check Point Inhibitor Resistance

July 7, 2021
REHOVOT, Israel

 

REHOVOT, Israel —July 07, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14, 2021 at 10am Eastern Time.

 

The webinar will feature a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who will discuss New Frontiers for Checkpoint Inhibitors in Immuno-Oncology. NeoTX’s management will also give an update on their Tumor Targeted Superantigen (TTS) platform’s lead candidate, naptumomab estafenatox (NAP) in overcoming resistance. NAP is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management will be available to answer questions following the formal presentations.

 

To register for the webinar, please click here.

 

Dr. Mario Sznol is Professor of Internal Medicine, Leader of the Melanoma-Renal Cancer Disease-Associated Translational Research Team, and Co-Leader of the Cancer Immunology Program at the Yale Cancer Center, New Haven, CT. Dr. Sznol graduated from Rice University and Baylor College of Medicine (BCM) in Houston, Texas. He trained in internal medicine at BCM and completed a medical oncology fellowship in the Department of Neoplastic Diseases, Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program of the National Cancer Institute, and was Head of the BES from 1994-1999. He attended on the inpatient units of the Biological Response Modifiers Program, NCI, from 1988-1996 and the Immunotherapy Service of the Surgery Branch, NCI, from 1997-1999. From 1999-2004, he served as Vice President of Clinical Development and Executive Officer of Vion Pharmaceuticals in New Haven, Connecticut, and joined the faculty at Yale in 2004. Dr. Sznol is a past President of the Society for Immunotherapy of Cancer. Dr. Sznol’s areas of interest include early drug development, immunotherapy clinical trials, and treatments for advanced melanoma and renal cancer.

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information,

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751-4366
cait@lifescicomms.com

NeoTX Announces FDA Clearance of IND for Phase 2 Clinical Trial of Naptumomab Estafenatox (NAP), its lead Tumor Targeted Superantigen Candidate

April 19, 2021
REHOVOT, Israel

REHOVOT, Israel — April 19, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for naptumomab estafenatox (NAP). NeoTX is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. NAP, the company’s lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.  NAP has demonstrated preliminary safety and anti-tumor activity in early-stage clinical trials in solid tumors.

 

“This FDA clearance is an exciting milestone for NeoTX,” said Asher Nathan, Ph.D., chief executive officer of NeoTX. “Preclinical and preliminary clinical studies have demonstrated that NAP has potential in combination with other treatment modalities. Non-small cell lung cancer is one of the deadliest cancers, and we are looking forward to assessing NAP in the clinic in combination with chemotherapy as a potential new treatment option after failure of current standards of care.”

 

The Phase 2a open label trial will evaluate NAP in combination with docetaxel in 35 patients with checkpoint inhibitor pretreated, advanced or metastatic non-small cell lung cancer.  The primary endpoint is objective response rate as measured by RECIST 1.1 criteria.  The trial will also evaluate safety, duration of response, progression free survival, overall survival, pharmacokinetics and pharmacodynamics.  

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information,

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751-4366
cait@lifescicomms.com

NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium

August 4, 2020
REHOVOT, Israel

REHOVOT, Israel – August 3, 2020 – NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted cancer immunotherapies, today announced it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place August 4-5, 2020. Chief Executive Officer, Asher Nathan, will deliver a corporate update to potential investors and strategic partners, among other various relevant audiences. The presentation will cover recent and upcoming Company milestones, as well as detail clinical progress of the Company’s lead candidate, naptumomab estafenatox (“Nap”), currently being evaluated in a Phase1b clinical trial for the treatment of advanced and metastatic solid tumors in combination with AstraZeneca’s (NYSE: AZN) checkpoint inhibitor IMFINZI® (durvalumab).  

Presentation Details:

Date:               Wednesday, August 5, 2020

Time:               9:30 a.m. EDT

Registration:  Register Here

About the LifeSci Partners Private Company Virtual Summer Symposium

LifeSci Partners is hosting its inaugural Private Healthcare Company Virtual Summer Symposium on August 4 and 5, 2020. The Symposium will feature presentations by executives from more than 130 private healthcare companies in both the biopharma and medical device sectors as well as panel discussions with healthcare industry leaders, venture capital and investment communities. The format will include 25-minute presentations from each participating company followed by a moderated question and answer segment.

About NeoTX:
NeoTX is a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The company’s lead STR molecule, naptumomab estafenatox (Nap) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com.

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751-4366
cait@lifescicomms.com

NeoTX Closes $45 Million Series C Financing

February 19, 2020
REHOVOT, Israel

NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies, has closed a $45 million Series C financing.  In conjunction with the financing, former vice chairman of The Blackstone Group, J. Tomilson Hill, Chairman of NDFOS Co., Ltd, Andrew Kim, Paul T. Marinelli and Nobel laureate Dr. Roger Kornberg, the chief scientific officer of NeoTX have joined the NeoTX Board of Directors. To date, NeoTX has raised over $60 million. NeoTX plans to use the Series C proceeds to advance its STR platform for the treatment of advanced and metastatic solid tumors as well as to in-license new technologies.

“With the funds raised in this financing, we intend to complete the dose escalation phase of the Phase 1b trial of naptumomab estafenatox (“Nap”) in combination with durvalumab  and continue to develop our patented STR platform,” said Asher Nathan, chief executive officer of NeoTX. “Our platform, which uniquely leverages the body’s natural antibacterial immune response to selectively redirect T cells to kill the tumor, has the potential to be applicable in a variety of solid tumor indications and in combination with other immunotherapies. We look forward to the clinical advancement of Nap and expanding our platform in order to provide new options to patients suffering from advanced cancers.”

The open-label, multicenter, dose-finding Phase 1b study of Nap (NCT03983954) is currently enrolling. Patients are dosed with a combination of Nap and AstraZeneca’s (NYSE: AZN) checkpoint inhibitor IMFINZI® (durvalumab). NeoTX aims to establish the maximum tolerated dose before advancing to a larger cohort expansion phase in the Unites States.

About NeoTX:
NeoTX is a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The company’s lead STR molecule, naptumomab estafenatox (Nap) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com.

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751-4366
cait@lifescicomms.com

NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

November 4, 2019

REHOVOT, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) — NeoTX Therapeutics, Ltd. today announced a presentation on the company’s lead candidate from its Selective T cell Redirection (STR) platform, naptumomab estafenatox (Nap), at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland. The poster presentation will highlight preclinical data demonstrating that Nap and checkpoint inhibitors work synergistically to induce a prolonged and protective immune response against solid tumors.

Details on the presentation are as follows:

Abstract Title: Selective T cell Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor
Abstract Number: P657
Presenter: Meir Azulay, Ph.D.
Session Date & Time: Friday, November 8, 2019, 12:30 – 2:00 p.m. and 6:30 – 8:00 p.m. EST

NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors

October 28, 2019

Dose-escalation study to determine maximum tolerated dose ahead of Phase 2 cohort expansion study

Milestone marks initiation of studies in the NeoTX-AstraZeneca collaboration to study Nap in combination with durvalumab

REHOVOT, Israel, Oct. 28, 2019 (GLOBE NEWSWIRE) —  NeoTX Therapeutics, Ltd. today announced the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (Nap) in combination with AstraZeneca’s checkpoint inhibitor IMFINZI® (durvalumab) for the treatment of advanced or metastatic solid tumors. The company aims to establish the maximum tolerated dose in the dose-escalation Phase 1b study before advancing to a cohort expansion study.

“The dosing of the first patient in our Phase 1b trial is a significant milestone for NeoTX, as it is our first clinical-stage molecule developed with our Selective T Cell Redirection (STR) platform,” said Asher Nathan, Ph.D., chief executive officer of NeoTX. “Previous clinical studies have shown Nap to be well-tolerated, and preclinical work conducted by the NeoTX team supports its broad potential in treating advanced and metastatic tumors, especially in combination with checkpoint inhibitors. We’re looking forward to bringing this therapy to patients suffering from advanced cancers that have thus far been unresponsive to therapy with checkpoint inhibitors alone.”   

The open-label, multicenter, dose-finding Phase 1b trial (NCT03983954) will enroll patients with previously treated advanced or metastatic tumors. Patients will be treated with a combination of Nap and durvalumab.

About the STR platform
The STR platform leverages the body’s natural antibacterial immune response to selectively expand and redirect T cells to rapidly infiltrate and kill tumor cells, offering unique advantages in the field of T cell redirection. STR compounds induce the activation and expansion of specific T cells outside of the tumor microenvironment and redirect the T cells to attack the tumor cells.

About naptumomab estafenatox (Nap)
Naptumomab estafenatox is the lead compound in NeoTX’s STR platform and is designed to target the 5T4 antigen that is present on many tumors.

Naptumomab estafenatox was licensed from Active Biotech in 2016. Active Biotech AB (publ) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Please visit www.activebiotech.com for more information.

About Durvalumab

Durvalumab (IMFINZI®) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses.

Imfinzi is approved for unresectable, Stage III non-small cell lung cancer (NSCLC) in more than 50 countries including the US, in the EU, and Japan based on the Phase III PACIFIC trial. Imfinzi is also approved for previously-treated patients with advanced bladder cancer in 10 countries, including the US.

As part of a broad development program, Imfinzi is also being tested as a monotherapy and in combination with tremelimumab, an anti-CTLA4 monoclonal antibody and potential new medicine, as a treatment for patients with NSCLC, small cell lung cancer, bladder cancer, head and neck cancer, liver cancer, cervical cancer, biliary tract cancer and other solid tumors.

About NeoTX

NeoTX Therapeutics Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

February 11, 2019

NeoTX Therapeutics, Ltd announced today that it has entered into a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN) global biologics research and development arm, MedImmune, to support Phase 1b/2 studies investigating NeoTX’s naptumomab estafenatox (“naptumomab”) in combination with IMFINZI® (durvalumab). These studies are expected to begin in 2019. Naptumomab is the lead drug in NeoTX’s novel Selective T cell Redirection (“STR”) platform.
Naptumomab’s dual mechanism of action coats the tumor with a target that can be easily identified by T cells and then primes and redirects specific activated T cells that can identify that target, to the tumor.
Durvalumab is a human monoclonal antibody that blocks the immune checkpoint protein, programmed death-ligand (PD-L1), and allows activated T cells to attack tumor cells.
The Phase 1b/2 studies will determine the maximum tolerated dose (MTD) of naptumomab in combination with durvalumab, evaluate the clinical response, safety and tolerability of the combination, as well as test for multiple pharmacodynamic parameters.
Under terms of the agreement, NeoTX and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in solid tumors. NeoTX will sponsor the study, while AstraZeneca will supply durvalumab. Up to 195 patients are planned to be enrolled in this multicenter, open-label study.
“We are pleased to work with AstraZeneca addressing the high unmet medical need of patients with tumors for which checkpoint inhibitor therapy has had little success,” said Asher Nathan, NeoTX Therapeutics’ Chief Executive Officer. “The safety profile of naptumomab alone and in combination with interferon has been demonstrated in clinical studies in hundreds of patients with solid tumors. Naptumomab can enhance T cell activation and infiltration in tumors and can remodel the immunosuppressive tumor microenvironment. In preclinical models, naptumomab has a synergistic effect with checkpoint inhibitors which could translate into durable responses in patients.”

About NeoTX:
NeoTX Therapeutics Ltd. is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology (www.NeoTX.com).
For more information contact
609 718 2305
CEO Asher Nathan x215 (asher@neotx.com) or
CFO Robert Harow x204 (robert@neotx.com).
About Naptumomab Estafenatox:
Naptumomab estafenatox is the lead compound in NeoTX’s STR platform. The STR platform offers unique advantages in the field of T cell redirection. STR compounds induce the activation and expansion of specific T cells outside of the tumor microenvironment and redirect the T cells to attack the tumor cells.
Naptumomab estafenatox was licensed from Active Biotech in 2016.
About Active Biotech:
Active Biotech A.B (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer.
About Durvalumab:
Durvalumab, a human monoclonal antibody directed against PD-L1, blocks PD-L1 interaction with PD-1 and CD80 on T cells, countering the tumor’s immune-evading tactics and inducing an immune response. As part of a broad development program, durvalumab is being investigated as monotherapy and in combination with immuno-oncology, small molecules, and chemotherapies across a range of tumors and stages of disease.

Various statements in this release concerning future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the “Risk Factors” sections of recent annual reports filed by the parties to this release. In addition, any forward-looking statements represent the parties’ views only as of the date of this release and should not be relied upon as representing their views as of any subsequent date. The parties do not assume any obligation to update any forward-looking statements unless required by law.